Journal of Neurology Research, ISSN 1923-2845 print, 1923-2853 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Neurol Res and Elmer Press Inc
Journal website https://www.neurores.org

Short Communication

Volume 14, Number 1, June 2024, pages 37-42


Non-Invasive Neuromodulation for Episodic and Chronic Migraine Headache: Preliminary Findings on Feasibility of At-Home Transcranial Direct Current Stimulation With Remote Supervision

Figure

Figure 1.
Figure 1. Satisfaction with the device and procedure (n = 16).

Tables

Table 1. Baseline Characteristics (N = 22)
 
CharacteristicsMedian (IQR) or N (%)
aRace analyses are White, Non-Hispanic vs. African American, Hispanic or Asian. bEducation analyses are completed high school and some college vs. completed college and graduate school. MSQ: Migraine-Specific Quality of Life; Ham-D: Hamilton Depression Scale; KPS: Karnofsky Performance Status: (100 - Normal, no complaints, no evidence of disease; 90 - Able to carry on normal activity, minor signs or symptoms of disease; 80 - Normal activity with effort, some signs or symptoms of disease; 70 - Cares for self, unable to carry on normal activity or do work).
Demographics
  Age37 (27 - 46)
  Gender17 F, 5 M
  Racea
    White, non-Hispanic15 (68%)
    African American2 (9%)
    Hispanic3 (14%)
    Asian2 (9%)
  Educationb
    Completed high school1 (5%)
    Some college4 (18%)
    Completed college16 (73%)
    Graduate school1 (5%)
  Marital status
    Single14 (64%)
    Married or living with partner8 (36%)
Clinical characteristics
  Migraine duration (years)17 (10 - 29)
  Chronic migraine status
    Episodic7 (32%)
    Chronic15 (68%)
  KPS
    701 (5%)
    808 (37%)
    9012 (55%)
    1001 (5%)
Baseline diary data/30 days
  Migraine days23 (11 - 28)
  Migraine attacks5 (2 - 6)
  Acute medication days6 (1 - 16)
  Acute medication doses11 (2 - 28)
  Average migraine pain intensity5 (4 - 6)
  Aura days0 (0 - 2)
  Nausea days2 (0 - 6)
  Photophobia days8 (2 - 24)
  Phonophobia days6 (2 - 16)
  MSQ total42 (38 - 48)
  MSQ role restriction23 (21 - 29)
  MSQ role prevention9 (6 - 11)
  MSQ emotion function10 (8 - 12)
  Ham-D9 (4 - 13)

 

Table 2. Adherence to the Prescribed 60-Day Intervention (N = 16)
 
Stimulation days, mean (SD)Stimulation days, rangeStimulation days, medianAdherence ≥ 80% of delivered sessions, N (%)Adherence 100% of delivered sessions, N (%)
SD: standard deviation.
Month 125.7 (5.2)10 - 3027.512 (75%)4 (25%)
Month 223.6 (8.8)3 - 3027.511 (68.8%)4 (25%)
Total 60-day period49.3 (13.2)13 - 6052.511 (68.8%)4 (25%)